OC 10X

Drug Profile

OC 10X

Alternative Names: OC-10X

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OcuCure Therapeutics
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy
  • No development reported Age-related macular degeneration

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In volunteers) in Bangladesh (Ophthalmic, Drops)
  • 01 Oct 2016 OcuCure Therapeutics terminates a phase II trial in Diabetic retinopathy in Bangladesh (Ophthalmic) (NCT02735369)
  • 01 Jun 2013 OcuCure Therapeutics completes a phase I trial in Healthy volunteers in Bangladesh (NCT01869933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top